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Abstract
Background: This study advances the clinical development of the RTS,S/AS01B candidate malaria vaccine to malaria
endemic populations. As a primary objective it compares the safety and reactogenicity of RTS,S/AS01B to the more
extensively evaluated RTS,S/AS02A vaccine.
Methodology: A Phase IIb, single centre, double-blind, controlled trial of 6 months duration with a subsequent 6 month
single-blind follow-up conducted in Kisumu West District, Kenya between August 2005 and August 2006. 255 healthy adults
aged 18 to 35 years were randomized (1:1:1) to receive 3 doses of RTS,S/AS02A, RTS,S/AS01B or rabies vaccine (RabipurH;
Chiron Behring GmbH) at months 0, 1, 2. The primary objective was the occurrence of severe (grade 3) solicited or
unsolicited general (i.e. systemic) adverse events (AEs) during 7 days follow up after each vaccination.
Principal Findings: Both candidate vaccines had a good safety profile and were well tolerated. One grade 3 systemic AE
occurred within 7 days of vaccination (RTS,S/AS01B group). No unsolicited AEs or SAEs were related to vaccine. A marked
increase in anti-CS antibody GMTs was observed post Dose 2 of both RTS,S/AS01B (31.6 EU/mL [95% CI: 23.9 to 41.6]) and
RTS,S/AS02A (16.7 EU/mL [95% CI: 12.9 to 21.7]). A further increase was observed post Dose 3 in both the RTS,S/AS01B
(41.4 EU/mL [95% CI: 31.7 to 54.2]) and RTS,S/AS02A (21.4 EU/mL [95% CI: 16.0 to 28.7]) groups. Anti-CS antibody GMTs
were significantly greater with RTS,S/AS01B compared to RTS,S/AS02A at all time points post Dose 2 and Dose 3. Both
candidate vaccines produced strong anti-HBs responses. Vaccine efficacy in the RTS,S/AS01B group was 29.5% (95% CI:
215.4 to 56.9, p=0.164) and in the RTS,S/AS02A group 31.7% (95% CI: 211.6 to 58.2, p=0.128).
Conclusions: Both candidate malaria vaccines were well tolerated over a 12 month surveillance period. A more favorable
immunogenicity profile was observed with RTS,S/AS01B than with RTS,S/AS02A.
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Introduction
Plasmodium falciparum is one of the most frequent causes of morbidity
and mortality in areas where it is endemic [1,2]. In Sub-Saharan
Africa, P. falciparum causes the deaths of between 0.5 and 2.0 million
children every year and is the most common reason for their admission
to hospital [3]. Economic models have indicated that malaria may
considerably retard economic development in African countries [4,5].
Despite successful activities over the past century to decrease the land
area suitable for malaria transmission, advances in understanding
malaria ecology, and the development of interventions, the number of
people at risk of malaria continues to increase [6]. As an adjunct to
other interventions, the development of a safe, effective and affordable
malaria vaccine is a critical global public health priority [7].
The RTS,S antigen adjuvanted with AS02A was developed by
GlaxoSmithKline (GSK) Biologicals and tested in collaboration
with the Walter Reed Army Institute of Research (WRAIR) since
1992 [8]. It is today the world’s leading malaria candidate vaccine.
The AS02 Adjuvant System contains an oil-in-water emulsion, the
immunostimulant monophosphoryl lipid A (MPL) and QS21 (a
natural saponin) molecule purified from the bark of the South
American tree Quillaja saponaria [9,10].
The RTS,S/AS02A vaccine has been shown to have an
acceptable safety profile, to be immunogenic and to provide
PLoS ONE | www.plosone.org 1 July 2009 | Volume 4 | Issue 7 | e6465complete or partial protection against infection in malaria-naı ¨ve
adults [11–16] undergoing experimental challenge. Similarly, this
vaccine has shown an acceptable safety profile, robust immuno-
genicity and has conferred partial protection against infection
and/or clinical malaria in adults [17–20] children [21–25], and
infants [26] living in malaria-endemic areas.
The RTS,S/AS01B formulation has been developed in parallel
with the aim of improving the immune response and vaccine
efficacy. The AS01 Adjuvant System is based on liposomes and
contains the same amounts of MPL and QS21 as AS02. Preclinical
studies suggested that the liposomal formulation AS01 is more
immunogenic than the oil-in-water emulsion formulation AS02
[27–29]. In healthy malaria-naı ¨ve adults both vaccines were
equally well tolerated, however, RTS,S/AS01B was significantly
more immunogenic than RTS,S/AS02A and showed a strong
trend for greater efficacy [30].
The aims of this study were to evaluate RTS,S/AS01B and
RTS,S/AS02A in adults in a malaria-endemic region. The
primary objective was to compare the safety profile of RTS,S/
AS01B to that of RTS,S/AS02A in adults to determine if RTS,S/
AS01B should proceed to evaluation in children. Secondary
objectives included evaluations of immunogenicity and efficacy.
Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
Ethics statement
The protocol was approved by the KEMRI and Kenya National
Ethical Review Committee, Nairobi, and the US Army Medical
Research and Materiel Command’s Human Subjects Research
Review Board, Fort Detrick, Maryland. The trial was undertaken
according to the International Conference on Harmonization,
Good Clinical Practice guidelines and was monitored by GSK
Biologicals.A Local SafetyMonitorand a SafetyMonitoring Group
closely reviewed the conduct and results of the trial.
Following an information campaign, local consultation, exhaus-
tive informed consent process and screening, 255 adult volunteers
between 18 and 35 years were enrolled to the trial (refer to Figure 1
for an overview of study recruitment). Written informed consent
or, in case of illiteracy, a thumb print in the presence of a literate
witness was obtained before study procedures began.
Participants
The trial was conducted at the KEMRI-Walter Reed Project’s
Kombewa Clinical Research Center in healthy adults almost
exclusively of the Luo tribe, predominantly Seme sub-tribe, aged
18 to 35 years recruited from Kombewa Division, Kisumu West
District, Nyanza Province of Western Kenya.
The climate is tropical. There are two intense malaria
transmission periods from April to August - the ‘long rains’ -
and from October to December - the ‘short rains’. Malaria disease
is primarily a result of infection with P. falciparum.
All volunteers had their medical histories taken and a full medical
examination was conducted. Volunteers were excluded if they had
any confirmed or suspected immunodeficient condition, history of
allergic reactions to immunizations, history of neurologic disorders
or seizures, clinically significant acute disease at time of enrolment,
were pregnant (or lactating) or planning to become pregnant, were
positive for HBsAg, a history of drug or alcohol abuse, were positive
for homozygous sickle cell disease, or had significantly abnormal
tests of renal function, or of hepatic or hematologic parameters.
Female volunteers of childbearing potential were only enrolled if
they had used adequate contraceptive precautions for 30 days prior
to vaccination and agreed to continue such precautions for two
months after completion of the vaccination series.
Procedures and interventions
Any volunteers who were found to have a medical condition
that excluded them from participation in the trial were informed at
a private appointment with a member of the clinical staff. Time
was taken to fully counsel the volunteer on the causes and severity
of their condition, any implications the condition might have on
their lifestyle, and evaluation and treatment options. Where
appropriate, volunteers were then referred to speciality or sub-
speciality physicians in the local area capable of dealing with the
volunteers’ condition in an appropriate manner.
Recipients of candidate vaccine were administered 50 mgo f
lyophilized RTS,S reconstituted with 500 mL of either AS02A or
AS01B Adjuvant Systems. Both candidate and control vaccines
were administered intramuscularly to the deltoid muscle of the
non-dominant arm on a 0, 1, 2-month schedule (Figure 2).
Vaccinees were observed for 30 minutes following each vaccina-
tion.
Volunteers were followed daily for the solicited adverse events
(AEs) of pain, swelling, fever, fatigue, gastrointestinal problems,
headache, joint pain and muscle ache for a total of 7 days
following each vaccination and for unsolicited AEs for 30 days
following each dose; serious AEs (SAEs) were recorded throughout
the study period. Blood draws for safety evaluation and humoral
responses were taken at scheduled time points during the study
(Figure 2).
The study population was drawn from one-mile radius
catchment areas around each of 13 field stations. The field
stations were staffed 24 hours/day throughout the study period to
facilitate referral medical care and were 0.5 to 10 miles distant
from the Kombewa Clinical Research Center.
One week prior to vaccine Dose 3 all volunteers were presump-
tively treated with three daily doses of MalaroneH (atovaquone and
proguanil hydrochloride, GSK, Uxbridge, UK) administered
under direct observation by the study staff. All subjects were re-
checked for asexual P. falciparum parasitemia one week post Dose 3.
Any subject who tested positive would have been treated with a
second line drug, and the absence of parasitemia again confirmed
just prior to inclusion in the efficacy evaluation which started 2
weeks after Dose 3.
Efficacy evaluation included both active detection of infection
(ADI) with weekly blood draws and passive case detection in all
volunteers presenting with symptoms consistent with malaria.
Objectives
The study was a Phase II, controlled, randomized, double-blind
study of 12 months duration of two candidate malaria vaccine
formulations, RTS,S/AS02A and RTS,S/AS01B. The study was
prospectively designed to analyse safety, immunogenicity and
efficacy endpoints over a 6 month surveillance period in a double-
blinded fashion. A subsequent 6 month single-blind follow-up was
defined for the assessment of safety and immunogenicity . The
primary objective was to compare the safety and reactogenicity of
RTS,S/AS01B to RTS,S/AS02A in adults in Kenya. Secondary
objectives were to describe the safety of the vaccine candidates,
describe antibody responses to the circumsporozoite (anti-CS)
antigen and hepatitis B surface antigen (anti-HBs) and to assess
efficacy against infection with P. falciparum malaria (defined as P.
falciparum asexual parasitemia.0/mL by microscopy) over a period
of 14 weeks starting two weeks post Dose 3.
RTS,S Vaccine in Kenyan Adults
PLoS ONE | www.plosone.org 2 July 2009 | Volume 4 | Issue 7 | e6465Figure 1. CONSORT diagram for study participants. 176 failed eligibility criteria: 13 outside age range [18–35]; 9 not available for the whole
study duration (12 months); 44 not free of obvious health problem (med history/clin exam); 14 female of childbearing potential not using adequate
contraceptives; 8 confirmed or suspected HIV; 10 acute disease at time of enrolment; 27 acute or chronic clinically significant pulmonary,
cardiovascular hepatic or renal functional abnormality; 6 ALT outside range; 15 hemoglobin outside range; 9 history of chronic alcohol/drug use; 21
other (including pregnant, administration of IG/blood products, sickle cell disease, HBsAg positive, other safety labs outside range, history of seizures,
or allergic reactions, planned administration of non-study vaccine). Note: Underlying medical conditions were not detected at screening. ADI: active
detection of infection. * These subjects did not complete ADI assessments, but were followed up for safety assessments and appear in the total of
completed single-blind phase.
doi:10.1371/journal.pone.0006465.g001
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The analysis for safety was conducted on the total vaccinated
cohort (defined as all subjects receiving at least one dose of study
vaccine).
The primary safety outcome was the occurrence of grade 3
solicited or unsolicited general reactions (i.e. systemic reactions)
after each vaccination during a 7 day follow-up period. Grade 3
general reactions (solicited or unsolicited) were defined as those
that prevented normal daily activity, or in the case of fever an oral
temperature .39.0uC. Grade 3 solicited pain at the injection site
was defined as preventing normal daily activities, or in the case of
swelling at the injection site, swelling that exceeded 50 mm in
diameter. Secondary safety outcomes included the occurrence of
SAEs until 10 months post Dose 3, unsolicited AEs after each
vaccination over a 30 day follow-up period (day of vaccination and
29 subsequent days), solicited general and local reactions over a 7
day follow-up period (day of vaccination and 6 subsequent days)
after each vaccination, abnormal hematological, renal, and
hepatic parameters.
Outcomes: immunogenicity
The primary analysis for immunogenicity was conducted on the
ATP cohort for immunogenicity, defined as all evaluable subjects
(i.e. those meeting all eligibility criteria, complying with the
procedures defined in the protocol, with no elimination criteria
during the study) for whom data concerning immunogenicity
endpoint measures were available.
Anti-CS and anti-HBs humoral responses were evaluated as
secondary outcomes: anti-CS at baseline, 1 month post Dose 2, 1
month post Dose 3, 4 months post Dose 3 and 10 months post
Dose 3, and anti-HBs at baseline, 1 month post Dose 3 and 10
months post Dose 3. Antibody levels against CS were measured in
Elisa units/milliliter (EU/mL) by standard ELISA methodology
using plate-adsorbed R32LR antigen [NVDP(NANP)15]2LR [24].
Anti-HBsAg was measured using a commercially available ELISA
immunoassay (AUSAB EIA test kit from Abbott).
Outcomes: efficacy
The primary analysis for efficacy was conducted on the ATP
cohort for efficacy defined as all evaluable subjects (i.e. those
meeting all eligibility criteria, complying with the procedures
defined in the protocol, with no elimination criteria during the
study) for whom data concerning efficacy endpoint measures were
available.
First episodes of infection with P. falciparum (first recording of
infection with asexual stage parasites detected by ADI or passive
case detection)were assessed by weekly sampling over a period
starting 14 days after Dose 3 and extending for a 14 week
duration. A cross-sectional evaluation of asexual P. falciparum
parasitemia (prevalence and density) at 16 weeks post Dose 3 was
conducted. Parasitemia was determined by microscopy. Each slide
was read independently by two microscopists, each of whom
examined 100 oil immersion fields before declaring a slide to be
negative. Parasite density was assessed by counting the number of
asexual parasites per 200 leukocytes. Parasite densities were then
calculated using a concomitant leukocyte count.
The percentage change in hemoglobin value between baseline
and 16 weeks post Dose 3 was an exploratory outcome.
Sample Size
For the primary objective, the study had a 90% power to detect
a difference between the proportion of subjects experiencing a
grade 3 solicited or unsolicited general reaction following
vaccination, should the difference in the proportion afflicted
exceed approximately 20% to 30%, depending on the rates in the
control group (rates of between 5% and 50% were assumed).
For the secondary vaccine efficacy endpoint, the study had 90%
power to detect significant (p,0.05) vaccine efficacy of either
candidate malaria vaccine versus control assuming an infection
rate of 72% over the 14 week period for surveillance of infection
and a true vaccine efficacy of 45%.
Randomization Procedures: sequence generation,
allocation concealment, implementation
Volunteers were randomized 1:1:1 to receive RTS,S/AS02A or
RTS,S/AS01B or RabipurH. A randomization list (block random-
ization) was provided and subjects were allocated to treatment on
the day of first dose. Subjects were allocated sequentially to
treatment numbers in the order that they presented for
vaccination. Treatment numbers were assigned to vaccines with
a randomization list generated using a standard SASH program
(Statistical Analysis System).
Blinding
Due to the differences in visual appearance of each of the study
vaccines, blinding was maintained by preparation of the vaccines
by the pharmacy staff in an area separate from where vaccination
occurred. Post-vaccination evaluations of AEs were conducted by
a separate team.
Statistical methods
Safety. Analysis was carried out according to a report and
analysis plan established before unblinding of trial data.
The proportion of subjects with a grade 3 solicited or unsolicited
general reaction, following each vaccination, was tabulated with
Figure 2. Study design overview. ADI=active detection of infection. CS=circumsporozoite protein.
doi:10.1371/journal.pone.0006465.g002
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were conducted using Fisher’s Exact Test. The proportion of
subjects experiencing SAEs or AEs as classified at the MedDRA
(Medical Dictionary for Regulatory Activities) preferred term level
was tabulated by group. The percentage of subjects experiencing
AEs and the percentage of doses followed by AEs were tabulated
by group. Fever, temperature in 0.5uC increments, grade 3 events,
and the relationship of events to vaccination as judged by the
investigator were investigated.
At each blood sampling timepoint biochemical parameters
(ALT and creatinine) above normal range and hematological
parameters (hemoglobin, total white blood cell count, platelets and
absolute lymphocyte count) below normal range were described.
Immunogenicity. Geometric mean titers (GMTs) of anti-CS
and anti-HBs antibodies, seropositivity rates of anti-CS and anti-
HBs antibodies and seroprotection rates of anti-HBs antibodies
were summarized with 95% CI. Analyses by vaccine group and by
infection status (subjects were regarded as ‘non-infected’ if no
malaria parasites were detected during the active detection of
cases) were performed.
Efficacy. Vaccine efficacy (VE) against infection was assessed
with Cox regression models, defined as 1 minus the hazard ratio.
Time at risk was corrected for absences from the study area and
for antimalarial treatment. The proportional hazards assumption
was investigated graphically, using a test based on the Schoenfeld
residuals. An adjusted analysis for VE was performed for
covariates of age, sickle cell trait, village of residence, and
distance of residence from the Kombewa Clinic. Bednets were
not distributed as part of the trial and data were not collected on
the use of bednets during the trial.
Prevalence and density of asexual P. falciparum parasitemia was
also assessed at 16 weeks post Dose 3 (end of the double-blind
phase).Assessment ofparasiteprevalencewasassessedusingFisher’s
exact test. The percentage change in hemoglobin between baseline
and the end of the double-blind phase of the study was assessed.
Analyses were done using SAS version 8 (SAS, Cary, NC, USA).
Results
Participant flow
483 volunteers were screened and 255 were enrolled to the
study and were evaluated for safety; 85 to each vaccine group (see
Figure 1). 237 subjects received all 3 vaccine doses as scheduled
and 228 were evaluable for surveillance for infection.
Recruitment
Recruitment commenced in July 2005. Vaccination took place
between August and October 2005; all three doses were completed
just prior to a period of increased malaria transmission (the short
rainy season). Surveillance for infection ran from October 2005 to
January 2006. The study completed in August 2006.
Baseline Data
There was no significant difference in baseline characteristics
between the three study groups (Table 1). The According to
Protocol (ATP) and Total vaccinated cohorts were comparable.
Numbers analyzed
All 255 planned subjects received at least Dose 1 of vaccine and
were included in the Total vaccinated cohort analysis. 222 subjects
Table 1. Baseline characteristics and distribution of covariates of study participants (Total vaccinated cohort).
RTS,S/AS01B N=85 RTS,S/AS02A N=85 Rabies N=85 Total N=255
n% n% n% n%
Age (years) Mean 24.9 – 25.2 – 26.1 – 25.4 –
Range 17 to 35 18 to 35 18 to 35 17 to 35
Gender Female 21 24.7 19 22.4 12 14.1 52 20.4
Male 64 75.3 66 77.6 73 85.9 203 79.6
Village of residence ABOL 6 7.1 6 7.1 4 4.7 16 6.3
BARKORWA 3 3.5 3 3.5 6 7.1 12 4.7
GOT AGULU 7 8.2 7 8.2 5 5.9 19 7.5
KITARE 12 14.1 8 9.4 9 10.6 29 11.4
KUOYO KOWE 2 2.4 1 1.2 3 3.5 6 2.4
MANYWANDA 3 3.5 4 4.7 5 5.9 12 4.7
MIRIERI 7 8.2 7 8.2 6 7.1 20 7.8
NDURU KADERO 5 5.9 6 7.1 2 2.4 13 5.1
ORUGA 6 7.1 7 8.2 11 12.9 24 9.4
OSEWRE 6 7.1 4 4.7 4 4.7 14 5.5
RANEN 5 5.9 2 2.4 0 0.0 7 2.7
RERU 2 2.4 5 5.9 1 1.2 8 3.1
WRP 21 24.7 25 29.4 29 34.1 75 29.4
Distance from Kombewa Clinic 0–5 km 21 24.7 25 29.4 29 34.1 75 29.4
5–10 km 16 18.8 15 17.6 13 15.3 44 17.3
10–20 km 48 56.5 45 52.9 43 50.6 136 53.3
Sickle Cell Trait positive 19 22.4 19 22.4 23 27.1 61 23.9
doi:10.1371/journal.pone.0006465.t001
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recipients of RTS,S/AS01B, 74 recipients of RTS,S/AS02A,
and 73 recipients of rabies vaccine). 228 subjects were included in
the ATP cohort for efficacy (74 RTS,S/AS01B, 79 RTS,S/
AS02A, and 75 rabies vaccine).
Outcomes and estimation
Safety outcomes. There was only one grade 3 general
symptom occurring within 7 days of vaccination (primary
endpoint). One recipient of RTS,S/AS01B had a fever of
39.7uC (grade 3) one day after receiving Dose 2 in association
with a confirmed episode of malaria (P. falciparum density 4735
parasites/mL).
There were similar rates of solicited general symptoms,
irrespective of intensity, in all three groups (96.5% RTS,S/
AS01B, 94.1% RTS,S/AS02A and 96.5% control, per dose). Most
reactions were mild and transient. The frequency of solicited local
and general symptoms, overall and by dose, is provided in Table 2.
Injection site pain was the most frequently reported local
symptom in all vaccine groups. The incidence of pain was
significantly lower in the RTS,S/AS01B group (reported following
54.5% of doses) compared to the RTS,S/AS02A group (reported
following 67.2% of doses) (p=0.005); pain was reported following
27.5% of doses of rabies vaccine. The incidence of swelling was
also slightly lower in the RTS,S/AS01B group (following 5.0% of
doses) compared to the RTS,S/AS02A group (following 8.9% of
Table 2. Incidence of solicited local and general adverse events within 7 days per dose and overall per dose (Total vaccinated
cohort).
RTS,S/AS01B RTS,S/AS02A Rabies vaccine
All Grade 3 All Grade 3 All Grade 3
Nn%Nn % Nn%Nn % Nn % N n %
Pain Dose 1 85 58 68.2 85 0 0.0 85 72 84.7 85 1 1.2 85 18 21.2 85 0 0.0
Dose 2 80 42 52.5 80 0 0.0 82 54 65.9 82 0 0.0 82 26 31.7 82 0 0.0
Dose 3 77 32 41.6 77 0 0.0 80 40 50.0 80 0 0.0 80 24 30.0 80 0 0.0
Overall 242 132 54.5 85 0 0.0 247 166 67.2 247 1 0.4 247 68 27.5 85 0 0.0
Swelling Dose 1 85 7 8.2 85 0 0.0 85 19 22.4 85 4 4.7 85 2 2.4 85 0 0.0
Dose 2 80 3 3.8 80 0 0.0 82 1 1.2 82 0 0.0 82 0 0.0 82 0 0.0
Dose 3 77 2 2.6 77 0 0.0 80 2 2.5 80 0 0.0 80 0 0.0 80 0 0.0
Overall 242 12 5.0 85 0 0.0 247 22 8.9 247 4 1.6 247 2 0.8 85 0 0.0
Fatigue Dose 1 85 19 22.4 85 0 0.0 85 17 20.0 85 0 0.0 85 19 22.4 85 0 0.0
Dose 2 80 15 18.8 80 0 0.0 82 10 12.2 85 0 0.0 82 10 12.2 82 0 0.0
Dose 3 77 9 11.7 77 0 0.0 80 6 7.5 80 0 0.0 80 6 7.5 80 0 0.0
Overall 242 43 17.8 85 0 0.0 247 33 13.4 85 0 0.0 247 35 14.2 85 0 0.0
Fever Dose 1 85 7 8.2 85 0 0.0 85 6 7.1 85 0 0.0 85 7 8.2 85 0 0.0
Dose 2 80 7 8.8 80 1 1.3 82 3 3.7 82 0 0.0 82 3 3.7 82 0 0.0
Dose 3 77 7 9.1 77 0 0.0 80 5 6.3 80 0 0.0 80 2 2.5 80 0 0.0
Overall 242 21 8.7 242 1 0.4 247 14 5.7 85 0 0.0 247 12 4.9 85 0 0.0
Gastrointestinal Dose 1 85 15 17.6 85 0 0.0 85 12 14.1 85 0 0.0 85 21 24.7 85 0 0.0
Dose 2 80 15 18.8 85 0 0.0 82 12 14.6 82 0 0.0 82 12 14.6 82 0 0.0
Dose 3 77 18 23.4 77 0 0.0 80 18 22.5 80 0 0.0 80 11 13.8 80 0 0.0
Overall 242 48 19.8 85 0 0.0 247 42 17.0 85 0 0.0 247 44 17.8 85 0 0.0
Headache Dose 1 85 34 40.0 85 0 0.0 85 44 51.8 85 0 0.0 85 33 38.8 85 0 0.0
Dose 2 80 24 30.0 80 0 0.0 82 26 31.7 82 0 0.0 82 23 28.0 82 0 0.0
Dose 3 77 26 33.8 77 0 0.0 80 25 31.3 80 0 0.0 80 11 13.8 80 0 0.0
Overall 242 84 34.7 85 0 0.0 247 95 38.5 85 0 0.0 247 67 27.1 85 0 0.0
Joint pain at other location Dose 1 85 8 9.4 85 0 0.0 85 8 9.4 85 0 0.0 85 12 14.1 85 0 0.0
Dose 2 80 11 13.8 80 0 0.0 82 8 9.8 82 0 0.0 82 4 4.9 82 0 0.0
Dose 3 77 8 10.4 77 0 0.0 80 6 7.5 80 0 0.0 80 6 7.5 80 0 0.0
Overall 242 27 11.2 85 0 0.0 247 22 8.9 85 0 0.0 247 22 8.9 85 0 0.0
Muscle aches Dose 1 85 14 16.5 85 0 0.0 85 9 10.6 85 0 0.0 85 15 17.6 85 0 0.0
Dose 2 80 5 6.3 80 0 0.0 82 7 8.5 82 0 0.0 82 6 7.3 82 0 0.0
Dose 3 77 8 10.4 77 0 0.0 80 7 8.8 80 0 0.0 80 8 10.0 80 0 0.0
Overall 242 27 11.2 85 0 0.0 247 23 9.3 85 0 0.0 247 29 11.7 85 0 0.0
N=number of administered doses.
n/%=number/percentage of doses followed by at least one type of symptom.
doi:10.1371/journal.pone.0006465.t002
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vaccine. Five grade 3 solicited local AEs were reported, all
occurring in the RTS,S/AS02A group (1 pain, 4 swelling). All
severe events occurred after Dose 1 of RTS,S/AS02A and all
resolved within the 7 day follow-up period.
96.1% of subjects reported an unsolicited AE within 30 days of
vaccination; four were grade 3 (3 RTS,S/AS01B, 1 rabies). No
unsolicited AE was judged to be related to vaccination by the
investigator.
Fourteen subjects had hemoglobin (Hb) levels below the normal
range (males,11 g/dL, females,9.5 g/dL) (8 RTS,S/AS01B, 4
RTS,S/AS02A, 2 rabies) the majority occurring 6 days post Dose
1 (RTS,S/AS01B n=4; RTS,S/AS02A n=1; rabies n=1) and 6
days post Dose 3 (RTS,S/AS01B n=1; RTS,S/AS02A n=1;
rabies n=1). The lowest recorded Hb values in the RTS,S/AS01B
group ranged from 8.5–10.5 g/dL, in the RTS,S/AS02A group
from 9.1–10.6 g/dL and in the rabies vaccine group from 8.4–
9.9 g/dL. Hemoglobin levels had not normalised by the last
laboratory assessment in 7 subjects (5 RTS,S/AS01B, 2 RTS,S/
AS02A). The low hemoglobin was attributed, in the 5 subjects
from the RTS,S/AS01B group, to chronic anemia, microcytic
anemia, infectious bloody diarrhea, immunosuppression and
pregnancy, and in the 2 subjects from the RTS,S/AS02A group,
to microcytic anemia in both cases.
Few subjects had WBC levels below the normal range
(males,3610
3/mL, females,2.5 610
3/mL) (4 RTS,S/AS01B, 2
rabies group) or lymphocyte counts below the normal range
(,1610
3/mL) (2 RTS,S/AS01B, 1 rabies group). No subjects had
abnormal platelet levels (above 77 000 per mm
3) during the study.
Eight subjects had ALT levels above the normal range
(males$60 IU/mL, females$40 IU/mL) (5 RTS,S/AS02A, 3
rabies), first recorded 6 days post Dose 1 in all 5 subjects in the
RTS,S/AS02A group and 1 month post Dose 3 in all 3 subjects in
the rabies group. All out of range values were mild in intensity
(,2.56Upper Limit of Normal [ULN]), judged not to be clinically
significant and not investigated further.
Eleven subjects had bilirubin values above the normal range
(.1.48 mg/dL) which onset during the study (3 RTS,S/AS01B, 3
RTS,S/AS02A, 5 rabies group), first recorded 6 days post Dose 1
in 4 subjects (2 RTS,S/AS01B; 1 RTS,S/AS02A; 1 rabies) and 1
month post Dose 3 in 7 subjects (1 RTS,S/AS01B; 2 RTS,S/
AS02A; 4 rabies). The highest recorded bilirubin values in
recipients of RTS,S/AS01B were 1.50–2.65 mg/dL, in recipients
of RTS,S/AS02A 1.51–2.42 mg/dL and in recipients of rabies
vaccine 1.52–2.34 mg/dL. All bilirubin elevations were judged not
to be clinically significant and not investigated further. None were
associated with any other liver test abnormality. No subjects had
abnormal creatinine levels (outside range 0.45 to 1.0 mg/dL)
during the study.
Nine subjects became pregnant during the course of the study: 4
recipients of RTS,S/AS01B, 3 of RTS,S/AS02A, and 2 of rabies
vaccine. One recipient of RTS,S/AS01B had a stillbirth at 27
weeks of pregnancy for which no cause was identified. This
occurred 42 weeks after the administration of the third dose and
the blinded investigator considered the stillbirth unlikely to be
related to vaccination. In the other eight cases, the mothers gave
birth to healthy infants.
During the entire 12 month study duration, 5 subjects from the
RTS,S/AS01B group (5.9%), 1 subject (1.2%) from the RTS,S/
AS02A group and 5 subjects (5.9%) from the rabies group reported
at least one SAE. None were considered to be related to study
vaccine and none were fatal. No volunteer withdrew due to an AE.
SAEs resulting in hospitalisation were reported by two subjects
during the trial, both recipients of RTS,S/AS01B. One subject, a
26 year old woman was admitted to hospital 29 days post Dose 3
suffering from bleeding peptic ulcer disease. She was discharged
from hospital after two days. The second subject, a 36 year old
man, was diagnosed with pneumonia, pulmonary tuberculosis,
meningitis and HIV infection five months post Dose 3. Following
resolution of the meningitis, the subject was discharged with
medication for the tuberculosis and HIV infections. The volunteer
received counselling and was enrolled in a Ministry of Health
approved HIV care and treatment program.
Immunogenicity outcomes. Both malaria vaccines were
immunogenic for anti-CS antibodies, with RTS,S/AS01B
producing a significantly more robust response than RTS,S/
AS02A (Figure 3). Pre-vaccination anti-CS GMTs were low and
equivalent in the study groups. A marked increase in anti-CS
antibody GMTs was observed post Dose 2 of both RTS,S/AS01B
(31.6 EU/mL [95% CI: 23.9 to 41.6]) and RTS,S/AS02A
(16.7 EU/mL [95% CI: 12.9 to 21.7]). A further increase was
observed post Dose 3 in both the RTS,S/AS01B (41.4 EU/mL
[95% CI: 31.7 to 54.2]) and RTS,S/AS02A (21.4 EU/mL [95%
CI: 16.0 to 28.7]) groups. Anti-CS antibody GMTs were
significantly greater with RTS,S/AS01B compared to RTS,S/
AS02A 1 month post Dose 2 (Day 60, p#0.001), 1 month post
Dose 3 (Day 90, p#0.001), 4K months post Dose 3 (Month 6K;
p=0.003) and 10 months post Dose 3 (Month 12; p=0.002).
Although anti-CS antibody GMTs decreased at 6 and 10 months
post Dose 3, they remained higher in the RTS,S/AS01B
compared to the RTS,S/AS02A group, and significantly greater
in the candidate vaccine groups versus the rabies control group.
Both candidates produced strong anti-HBs responses (Table 3).
A marked increase in anti-HBs GMTs was observed in recipients
of candidate malaria vaccines 1 month post Dose 3 (Day 90);
GMTs were similar in the RTS,S/AS01B (1435 mIU/mL [95%
CI: 743 to 2771]) and RTS,S/AS02A (1714 mIU/mL [95% CI:
836 to 3515]) groups. Although anti-HBs antibody GMTs had
decreased at 6 and 10 months post Dose 3 in both the RTS,S/
AS01B and RTS,S/AS02A groups, GMTs were greater than the
rabies control group. At baseline, 40% of subjects in the RTS,S/
AS01B group and 49% of subjects in the RTS,S/AS02A group
were seroprotected for anti-HBs, and at 10 months post Dose 3
(Month 12) seroprotection had increased to 90% and 92%
respectively.
Efficacy outcomes. Table 4 and Figure 4 show the results for
VE against infection. VE in the RTS,S/AS01B group was 29.5%
(95% CI: 215.4 to 56.9, p=0.164 vs control) and in the RTS,S/
AS02A group 31.7% (95% CI: 211.6 to 58.2, p=0.128 vs
control); pooled data yielded an unadjusted VE of 30.9% (95% CI:
–4.7 to 54.4, p=0.081 vs control).
VE adjusted for age, sickle cell trait, village of residence and
distance of residence from the Kombewa Clinical Research Center
was 11.0% (95% CI 249.7 to 47.1: p=0.659) in recipients of
RTS,S/AS01B and 35.0% (95% CI 29.9 to 61.6: p=0.108) in
recipients of RTS,S/AS02A. Adjustments not taking into account
village of residence were similar to unadjusted analyses. Further
analyses were carried out to explain this finding, including an
examination of the role of baseline anti-CS antibody, but did not
reveal any obvious factors.
The proportion of subjects positive for parasitemia at 16 weeks
post dose 3 was similar in all the groups: RTS,S/AS01B 8.6%
(95% CI 3.2 to 17.7), RTS,S/AS02A 6.8% (95% CI 2.3 to 15.3)
and rabies control 4.2% (95% CI 0.9 to 11.9). The geometric
mean parasite densities of the positives were: RTS,S/AS01B 275
parasites per mL (95% CI 33 to 2295), RTS,S/AS02A 206 parasite
per mL (95% CI 51 to 843) and rabies control 521 parasites per mL
(95% CI 42 to 6470).
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baseline and 16 weeks post Dose 3 for any group (data not shown).
Association of immunogenicity and efficacy. Ancillary
analyses were performed to evaluate the association of anti-CS
antibodies with VE, irrespective of vaccine group. The analysis
was restricted to recipients of candidate malaria vaccines and
compared anti-CS GMTs between subjects that did, and those
that did not, become infected with malaria during the 14 week
follow-up period, from 14 days to 4 months post Dose 3 (infection
was defined as P. falciparum asexual parasitemia .0/mL detected
Table 3. Seropositivity rates, seroprotection rates and GMTs for anti-HBs antibodies by vaccine group (ATP cohort for
immunogenicity).
Group Timing Seropositive Seroprotected GMTs (mIU/mL)
N n % 95% CI n % 95% CI value 95% CI
RTS,S/AS01B PRE 73 31 43 31 55 29 40 29 52 11 6 20
PIII(D90) 72 68 94 86 99 65 90 81 96 1435 743 2771
PIII(M12) 61 57 93 84 98 55 90 80 96 594 317 1112
RTS,S/AS02A PRE 70 38 54 42 66 34 49 36 61 18 9 35
PIII(D90) 72 68 94 86 99 67 93 85 98 1714 836 3515
PIII(M12) 62 59 95 87 99 57 92 82 97 636 342 1183
Rabies vaccine PRE 68 35 52 39 64 33 49 36 61 24 11 49
PIII(D90) 65 37 57 44 69 33 51 38 63 32 15 69
PIII(M12) 66 40 61 48 72 33 50 37 63 29 14 59
Seropositive$3.3 mIU/mL; Seroprotected$10 mIU/mL.
GMT=geometric mean antibody titer calculated on all subjects.
PRE=prevaccination; PIII(D90)=post Dose 3 (Day 90); PIII(M12)=post Dose 3 (Month 12).
doi:10.1371/journal.pone.0006465.t003
Figure 3. Anti-CS GMTs over time (ATP cohort for immunogenicity). Note: bars represent 95% confidence intervals.
doi:10.1371/journal.pone.0006465.g003
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assessment period, anti-CS antibody GMTs were higher in non-
infected compared to infected subjects, which was statistically
significant at 1 month post Dose 2 (Day 60; p,0.0001), 1 month
post Dose 3 (Day 90; p=0.0007) and 4K months post Dose 3
(Month 6 K;p ,0.0001) (Figure 5).
Discussion
Interpretation
This paper presents the first safety, immunogenicity, and
efficacy data for the candidate RTS,S malaria vaccine combined
with the novel Adjuvant System AS01B when administered to
adult subjects in a malaria endemic region.
Overall, both the RTS,S/AS02A and RTS,S/AS01B formula-
tions were shown to have a good safety profile and were well
tolerated. With respect to the primary endpoint of the study, the
occurrence of severe (grade 3) systemic reactions occurring for up
to 7 days after each vaccination, one severe event was observed
(fever) in the RTS,S/AS01B group and none in either the RTS,S/
AS02A candidate vaccine group or the rabies control group. The
investigator considered the fever to be unrelated to the study
vaccine and due to concurrent malaria. Additional safety and
reactogenicity data showed the RTS,S/AS01B candidate vaccine
to compare favorably to the RTS,S/AS02A candidate vaccine in
terms of solicited local events (pain and swelling). Both candidate
vaccines were well tolerated; no subject withdrew due to an AE
and no unsolicited AEs or serious AEs were considered to be
related to study vaccine.
The safety and tolerability of the RTS,S/AS02A candidate
vaccine observed in this study conducted in Kenyan adults is
consistent with studies conducted in young African children from
Figure 4. Vaccine Efficacy: reverse cumulative curve showing the time to infection with malaria by vaccine group (ATP cohort for
efficacy). Gr 1=RTS,S/AS01B; Gr 2=RTS,S/AS02A; Gr 3=Rabies; Day 0=14 days post Dose 3; ADI=Active Detection of Infection.
doi:10.1371/journal.pone.0006465.g004
Table 4. Vaccine efficacy against P. falciparum infection (ATP cohort for efficacy).
Group N n PYAR Rate Point estimate of VE unadjusted for covariates Point estimate of VE adjusted for covariates
*
% 95% CI P value % 95% CI P value
RTS,S/AS01B 74 28 14.1 1.99 29.5 215.4 56.9 0.164 11.0 249.7 47.1 0.659
RTS,S/AS02A 79 28 14.6 1.92 31.7 211.6 58.2 0.128 35.1 29.9 61.6 0.108
RTS,S/AS01B & RTS,S/AS02A 153 56 28.7 1.95 30.9 24.70 54.4 0.081 23.4 218.3 50.4 0.229
Rabies control 75 37 13.2 2.80 – – – – – – –
N=number of subjects.
n=number of subjects with an episode of parasitemia.
PYAR=person years at risk.
VE=vaccine efficacy.
*adjusted for age, sickle cell trait, village of residence and distance of residence from Kombewe clinic.
doi:10.1371/journal.pone.0006465.t004
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AS01B had never before been evaluated under field conditions;
evaluation of the safety and reactogenicity of RTS,S/AS01B in
adults is a crucial requirement before evaluation in children. The
favorable safety profile of RTS,S/AS01B supported progression of
this candidate vaccine to further studies in children [32].
Both candidate vaccines were immunogenic for anti-CS and
anti-HBs antibodies. The level of anti-CS response to the RTS,S/
AS02A vaccine was consistent with previous studies conducted in
African adults [17,18,20], and is generally lower than the anti-CS
responses to RTS,S/AS02A in malaria-naı ¨ve adults [11,14,15]
and in children [21,23,24]. In this study, the RTS,S/AS01B
vaccine demonstrated significantly higher anti-CS antibody
responses compared to RTS,S/AS02A confirming observations
from a previous study conducted in malaria-naı ¨ve adults at the
WRAIR [30]. Although GMTs for anti-CS antibodies had
decreased at 6 and 10 months after dose 3 of both candidate
vaccines, they remained significantly higher than the control
group.
The study population had substantial baseline seroprotective
anti-HBs levels in the RTS,S/AS01B and RTS,S/AS02A groups
(40% and 49% respectively). Seroprotective levels of anti-HBs
antibodies were readily attained with both candidate vaccines.
RTS,S/AS01B and RTS,S/AS02A resulted in equivalent anti-
HBs responses over a 12 month surveillance period. Although a
waning of GMTs against HBs was observed by 10 months post
Dose 3, group seroprotection rates were at least 90% for both
candidate malaria vaccines.
This study was underpowered to measure the vaccine efficacy of
the two candidate vaccine formulations compared to control based
on the observed attack rate of 50% (predicted rate was 72%). In
this study, vaccine efficacy in the RTS,S/AS01B group was 30%
(95% CI: 215 to 57, p=0.164), in the RTS,S/AS02A group 32%
(95% CI: 212 to 58, p=0.128) and pooling the two vaccines was
31% (95% CI: 24.7 to 54, p=0.081). The finding that the point
estimate of vaccine efficacy fell when adjusted for village of
residence from 30% to 11% is difficult to interpret. It was
unexplained by the known characteristics of the villages or
observed malaria transmission patterns. However confidence
intervals (250 to 47) were wide and do not support the hypothesis
that vaccine efficacy adjusted for village was different from the
unadjusted.
The efficacy results for the RTS,S/AS02A vaccine are
consistent with those obtained in naturally infected adults from
The Gambia in which vaccine efficacy against malaria infection
over a 15 week surveillance period was shown to be 34% (95% CI:
8.0 to 53, p=0.014) [18]. Also, in a Phase II experimental
challenge model in which RTS,S/AS01B was compared to
RTS,S/AS02A in malaria-naı ¨ve adults, efficacy against infection
was higher in the RTS,S/AS01B group (50% [95% CI: 32.9 to
67.1]) than the RTS,S/AS02A group (32% [95% CI: 17.6 to
47.6]) [30].
In this trial in adults, as in the experimental challenge studies
[11,14,15,33] and field studies [18] in adults with the candidate
RTS,S/AS02A vaccine, the degree of vaccine induced protection
was associated with the antibody response to circumsporozoite
protein. Subjects who were not infected with malaria during the
course of the study exhibited significantly higher anti-CS antibody
responses than subjects who became infected. Similarly, in field
studies a significant association of antibody response and vaccine
induced protection against infection was found in infants [26], but
not against disease in young children [21]. The efficacy results of
RTS,S/AS01B in this current trial and in the challenge model in
malaria-naı ¨ve adults [30] together with the significantly improved
immunogenicity of RTS,S/AS01B compared to RTS,S/AS02A in
both malaria-naı ¨ve adults and in semi-immune adults in this trial
strongly support the continued evaluation of RTS,S/AS01B in
children.
Generalisability
The safety and tolerability of RTS,S/AS02A shown in this
study are consistent with studies in young African children. This is
however the first study of RTS,S/AS01B in Africa; it demon-
strated favorable safety and reactogenicity and improved humoral
Figure 5. Anti-CS GMTs during efficacy surveillance by infection status (ATP cohort for efficacy).
doi:10.1371/journal.pone.0006465.g005
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Estimates of efficacy associated with RTS,S/AS01B were similar
to those of RTS,S/AS02A. It is therefore planned to conduct trials
of a pediatric formulation of the RTS,S/AS01 candidate vaccine
(RTS,S/AS01E) in children in Africa.
Overall evidence
This was a successful evaluation of the safety profiles of RTS,S/
AS01B and RTS,S/AS02A and supports the decision to progress
to the evaluation of a pediatric formulation of RTS,S/AS01
(RTS,S/AS01E) in children.
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